EN DE
Watch iZafe Group AB Series B for free: we tell you when fair value or trend changes.
Data-driven stock valuation

iZafe Group AB Series B (IZAFE-B) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of iZafe Group AB Series B stock SEK 0.15, price SEK 0.20, that is 27.4% below the price, quality 20 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0003656834

IG iZafe Group AB Series B logo Thin data Nov 10, 2026

iZafe Group AB Series B

IZAFE-B · ST
Expensive, weak quality

Our calculation puts a fair price 27% below what the stock costs today.

Low debt
Revenue last quarter +132% vs. a year ago.
Fair value kr 0.1466 · Overvalued
Quality 20/100
Weak Growth (revenue 5y −7.6 %/yr in SEK)
Negative free cash flow
Trails peers (2/7)
Narrow moat 4/100 · thin data
Thin data
Estimate
Watch iZafe Group AB Series B for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 2.62 kr 0.1840 Fair Value kr 0.1466 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.1840 – kr 2.62 · fair‑value band kr 0.1099 – kr 0.1832 · the kr 0.2020 price screens above the kr 0.1466 fair value. As of Nov 10, 2026.

Follow iZafe Group AB Series B in your weekly email

Every Wednesday you see whether iZafe Group AB Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home.

Show moreShow less

The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses.

It also offers Pilloxa, a platform that provides real-time insights and improved data quality to empower and motivate patients.

The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.

Stock analysis

iZafe Group AB Series B (IZAFE-B) currently trades at kr 0.2020, while our estimate is kr 0.1466, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.1099 (bear) to kr 0.1832 (bull), the price of kr 0.2020 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

iZafe Group AB Series B reported revenue of 6.0M SEK in FY2025 versus 442K SEK in FY2021, a compound +91.9%/yr. Reported net income was −16.7M SEK in FY2025.

Key figures

Market cap 87.0M SEK (≈ $8.8M) Micro · P/S ratio 14.1 · EPS (TTM) kr −0.0500 · Return on equity −163% · Return on assets (EBIT) −69.9% (5-year average) · Operating margin −285% · Revenue (TTM) 8.6M SEK · Revenue growth (YoY) +132%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 4 out of 100 (low confidence).

What moves the price

The share trades about 71% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −27%, IZAFE-B screens cheaper than that median.

Fair Value

Bear kr 0.1099 Fair Value kr 0.1466 Bull kr 0.1832
Price kr 0.2020 · Downside -27.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−24.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+101.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.6%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−136.0% (2020) → −307.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IZAFE-B screens overvalued: fair value 27% below the price. Compare with Intuitive Surgical, Inc →

Compare iZafe Group AB Series B with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −27.4% · Below median
Profitability
Return on assets −46.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 132.3% · Top 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 7.44× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 10.12× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs IZAFE-B
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs IZAFE-B
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs IZAFE-B
Medline Inc MDLN $40.91 $28.59 −30% vs IZAFE-B
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs IZAFE-B
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs IZAFE-B
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs IZAFE-B
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs IZAFE-B
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs IZAFE-B
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs IZAFE-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iZafe Group AB Series B: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "iZafe Group AB Series B Fair Value". https://www.fairvalue-calculator.com/stock/IZAFE-B

Frequently asked questions

Is iZafe Group AB Series B (IZAFE-B) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.1466 versus a price of kr 0.2020, about 27% lower (overvalued).
What is the fair value of IZAFE-B?
Our estimate for iZafe Group AB Series B is kr 0.1466 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.2020.
What is the quality score of IZAFE-B?
iZafe Group AB Series B has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iZafe Group AB Series B (IZAFE-B)?
Our calculated price target is the estimate of kr 0.1466 (as of Nov 10, 2026). Cautious scenario kr 0.1099, optimistic scenario kr 0.1832. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the iZafe Group AB Series B stock forecast for 2026?
Our estimate puts fair value at kr 0.1466, about 27% lower versus a price of kr 0.2020 (overvalued). Cautious scenario kr 0.1099, optimistic scenario kr 0.1832. The calculation is refreshed regularly with new filings.
What is the revenue of iZafe Group AB Series B (IZAFE-B)?
iZafe Group AB Series B reported trailing-twelve-month revenue of about 8.6M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of iZafe Group AB Series B (IZAFE-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iZafe Group AB Series B it is kr 0.1466 per share (as of Nov 10, 2026), against a price of kr 0.2020.
Is iZafe Group AB Series B stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IZAFE-B trades above its calculated fair value: price kr 0.2020, fair value kr 0.1466, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IZAFE-B?
No. The price is what the market pays today (kr 0.2020); the fair value is what the company's own numbers justify (kr 0.1466). For iZafe Group AB Series B the two are kr 0.0554 per share apart. That gap is exactly why we show both numbers side by side.
How much is iZafe Group AB Series B worth?
The market values iZafe Group AB Series B at about 87.0M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.2020; our models calculate a fair value of kr 0.1466 per share.
What do the bullish and bearish scenarios say about IZAFE-B?
Our models span a range for iZafe Group AB Series B: cautious scenario kr 0.1099, base kr 0.1466, optimistic kr 0.1832 per share (as of Nov 10, 2026, price kr 0.2020). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iZafe Group AB Series B (IZAFE-B)?
Balance-sheet figures for iZafe Group AB Series B (as of Nov 10, 2026): return on equity −162.6%. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is IZAFE-B from its 52-week high?
iZafe Group AB Series B trades at kr 0.2020, about 71% below its 52-week high of kr 0.7000 and 1% above the low of kr 0.2000 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1466 is for.
Which stocks are comparable to iZafe Group AB Series B?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iZafe Group AB Series B stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.2020, calculated fair value kr 0.1466 (−27%), Quality Score 20/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. iZafe Group AB Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iZafe Group AB Series B (IZAFE-B)?
The closing price on Nov 10, 2026 was kr 0.2020. Our estimate is kr 0.1466, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iZafe Group AB Series B right now?
The price sits above even our optimistic bull case (kr 0.1832). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of iZafe Group AB Series B

How large is the market capitalisation of iZafe Group AB Series B (IZAFE-B)?
The market capitalisation of iZafe Group AB Series B is 87.0M SEK (≈ $8.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iZafe Group AB Series B (IZAFE-B)?
The price-to-sales ratio of iZafe Group AB Series B is 14.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iZafe Group AB Series B (IZAFE-B)?
Earnings per share at iZafe Group AB Series B are kr −0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of iZafe Group AB Series B (IZAFE-B)?
The return on equity (ROE) of iZafe Group AB Series B is −163% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iZafe Group AB Series B (IZAFE-B)?
On an EBIT basis the return on assets of iZafe Group AB Series B is −69.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iZafe Group AB Series B (IZAFE-B)?
The operating margin of iZafe Group AB Series B is −285% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iZafe Group AB Series B (IZAFE-B)?
Revenue at iZafe Group AB Series B is growing +132% versus a year earlier (3y avg +102%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does iZafe Group AB Series B (IZAFE-B) generate?
The free cash flow of iZafe Group AB Series B is −14.6M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does iZafe Group AB Series B (IZAFE-B) hold?
iZafe Group AB Series B holds more cash than debt, 1.6M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch iZafe Group AB Series B in the live analysis

One click puts iZafe Group AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.